The first patient has been enrolled in the Phase II/III clinical trial of the novel TYK2 inhibitor Soficitinib for the treatment of urticaria.

NovaTech announced on February 13 that the company's independently developed novel TYK2 inhibitor, Soficitinib, has completed patient enrollment in Phase II/III clinical trials for the treatment of chronic idiopathic urticaria. This is the fifth indication for clinical trials conducted by Soficitinib.